Table 4.
Frequency of Receptive Anal Intercourse and Reported Stage 2 Adverse Events
| HEC (n = 12) | TFV (n = 12) | Total (n = 24) | p | |
|---|---|---|---|---|
| Sexual activity | ||||
| Na, median (IQR, min–max) | ||||
| RAI | 9, 0 (0–0, 0–7) | 20, 0 (0–3, 0–7) | 29, 0 (0–1, 0–7) | .35 |
| CRAI | 1, 0 (0–0, 0–1) | 2, 0 (0–0, 0–2) | 3, 0 (0–0, 0–2) | .99 |
| Stage 2 AE | ||||
| Nb, median (IQR) | ||||
| Gel related | 0 | 3, 0 (0–0) | 2, 0 (0–0) | .47 |
| Procedure related | 6, 0 (0–0.75) | 3, 0 (0–0) | 9, 0 (0–0) | .65 |
| Unrelated | 12, 2 (0–2) | 17, 1 (0–2) | 29, 1 (0–2) | .36 |
a
Total number of sex acts.
b
Total number of stage 2 AEs.
CRAI, condomless receptive anal intercourse; RAI, receptive anal intercourse.